Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 15;594(18):5285-301.
doi: 10.1113/JP272352. Epub 2016 May 29.

Ventromedial hypothalamic melanocortin receptor activation: regulation of activity energy expenditure and skeletal muscle thermogenesis

Affiliations

Ventromedial hypothalamic melanocortin receptor activation: regulation of activity energy expenditure and skeletal muscle thermogenesis

Chaitanya K Gavini et al. J Physiol. .

Abstract

Key points: The ventromedial hypothalamus (VMH) and the central melanocortin system both play vital roles in regulating energy balance by modulating energy intake and utilization. Recent evidence suggests that activation of the VMH alters skeletal muscle metabolism. We show that intra-VMH melanocortin receptor activation increases energy expenditure and physical activity, switches fuel utilization to fats, and lowers work efficiency such that excess calories are dissipated by skeletal muscle as heat. We also show that intra-VMH melanocortin receptor activation increases sympathetic nervous system outflow to skeletal muscle. Intra-VMH melanocortin receptor activation also induced significant changes in the expression of mediators of energy expenditure in muscle. These results support the role of melanocortin receptors in the VMH in the modulation of skeletal muscle metabolism.

Abstract: The ventromedial hypothalamus (VMH) and the brain melanocortin system both play vital roles in increasing energy expenditure (EE) and physical activity, decreasing appetite and modulating sympathetic nervous system (SNS) outflow. Because of recent evidence showing that VMH activation modulates skeletal muscle metabolism, we propose the existence of an axis between the VMH and skeletal muscle, modulated by brain melanocortins, modelled on the brain control of brown adipose tissue. Activation of melanocortin receptors in the VMH of rats using a non-specific agonist melanotan II (MTII), compared to vehicle, increased oxygen consumption and EE and decreased the respiratory exchange ratio. Intra-VMH MTII enhanced activity-related EE even when activity levels were held constant. MTII treatment increased gastrocnemius muscle heat dissipation during controlled activity, as well as in the home cage. Compared to vehicle-treated rats, rats with intra-VMH melanocortin receptor activation had higher skeletal muscle norepinephrine turnover, indicating an increased SNS drive to muscle. Lastly, intra-VMH MTII induced mRNA expression of muscle energetic mediators, whereas short-term changes at the protein level were primarily limited to phosphorylation events. These results support the hypothesis that melanocortin peptides act in the VMH to increase EE by lowering the economy of activity via the enhanced expression of mediators of EE in the periphery including skeletal muscle. The data are consistent with the role of melanocortins in the VMH in the modulation of skeletal muscle metabolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Activation of VMH melanocortin receptors increases EE, even in the absence of altered physical activity
Compared to vehicle microinjection, intra‐VMH microinjection of the mixed melanocortin receptor agonist MTII significantly increased (A) EE, (B) V˙O2 and (D) physical activity levels, and also (C) decreased the RER, implicating increased lipid oxidation. When activity levels and workload were equalized using a treadmill walking protocol, the ability of MTII to (E) elevate EE, (F) increase V˙O2 and (G) lower RER remained, indicating decreased locomotor efficiency. *Significantly different from vehicle, P < 0.05 (n = 10).
Figure 2
Figure 2. Intra‐VMH microinjections of the melanocortin receptor agonist MTII enhanced thermogenesis
A, change in BAT thermogenesis from baseline levels was significantly higher between 30 and 105 min after MTII microinjection compared to vehicle. B, gastroc muscle thermogenesis was significantly elevated above baseline levels starting 90 min after microinjection and continuing until the end of the 240 min measurement. C, when gastroc temperature was measured after activity levels and workload were equalized using a treadmill, the activity‐associated change in gastroc temperature was significantly higher after intra‐VMH MTII compared to vehicle. *Significantly different from vehicle, P < 0.05 (n = 8).
Figure 3
Figure 3. Time of day, indicated by ZT (lights on ZT0), influenced baseline gastroc muscle and BAT thermogenesis
A, baseline gastroc temperature and activity‐related gastroc heat dissipation was highest at ZT18, with the most ZT‐associated differences seen between baseline during the first 10 min of treadmill walking. B, BAT thermogenesis showed a similar pattern of baseline temperature, with treadmill walking activity inducing a significant suppression in temperature (* P < 0.05). C, mixed β‐adrenergic antagonist nadolol significantly suppressed baseline and activity‐related gastroc heat dissipation during 10 min of treadmill walking (* P < 0.05) (n = 8).
Figure 4
Figure 4. Intra‐VMH microinjection of the mixed melanocortin receptor agonist MTII increased skeletal muscle NETO, an indicator of sympathetic drive
In MTII‐injected rats compared to vehicle‐injected rats, NETO was significantly increased in all muscle groups examined, including the (A) quad, (B) lateral gastroc (C) medial gastroc, (D) soleus and (E) EDL. *Significantly greater than vehicle, P < 0.05 (n = 8 per group).
Figure 5
Figure 5. Intra‐VMH microinjection of the mixed melanocortin receptor agonist MTII elevates mRNA expression of mediators of energy expenditure in peripheral metabolic tissues, with some alteration in the protein content and phosphorylation
Relative to vehicle‐treated rats, rats with intra‐VMH melanocortin receptor activation had significantly elevated mRNA levels of UCP2 and 3, SERCA2 and PPARδ in the (A) quad and (B) gastroc muscles; quad also had significantly elevated SERCA1, whereas gastroc showed higher β2 adrenergic receptor (Beta 2) and PPARα and δ expression and lower expression of the Kir6.2 subunit of the ATP‐gated K+ channel. C, liver of MTII‐injected rats showed elevated expression UCP2 and PPAR isoforms α, δ, and γ. D, BAT showed elevated expression of UCP1 and PPAR isoforms α, δ and γ in MTII‐injected rats. E, western blots were used to measure protein and phosphoprotein expression levels. In MTII‐treated rats, the pAMPK‐to‐AMPK ratio was significantly elevated in (F) quad, (G) gastroc, (H) liver, (I) BAT and (J) WAT, whereas the pACC/ACC ratio was significantly elevated above vehicle‐treated levels in muscle and BAT only. Mean vehicle‐treated defined as 100%. *Intra‐VMH MTII‐injected rats vs. vehicle‐treated rats, P < 0.05. (n = 7 per group for mRNA, four or five per group for protein).

Comment in

  • How the brain tips the scale.
    Dunn J, Mittendorfer B. Dunn J, et al. J Physiol. 2016 Sep 15;594(18):5041-2. doi: 10.1113/JP272701. J Physiol. 2016. PMID: 27629075 Free PMC article. No abstract available.

Similar articles

Cited by

References

    1. Abreu‐Vieira G, Xiao C, Gavrilova O & Reitman ML (2015). Integration of body temperature into the analysis of energy expenditure in the mouse. Mol Metab 4, 461–470. - PMC - PubMed
    1. Takahashi Akira & Shimazu Takashi (1981). Hypothalamic regulation of lipid metabolism in the rat: effect of hypothalamic stimulation on lipolysis. J Auton Nerv Syst 4, 195–205. - PubMed
    1. Anand BK & Brobeck JR (1951). Localization of a “feeding center” in the hypothalamus of the rat. Proc Soc Exp Biol Med 77, 323–324. - PubMed
    1. Belgardt BF & Bruning JC (2010). CNS leptin and insulin action in the control of energy homeostasis. Ann NY Acad Sci 1212, 97–113. - PubMed
    1. Bonen A, Tandon NN, Glatz JF, Luiken JJ & Heigenhauser GJ (2006). The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Int J Obes (Lond) 30, 877–883. - PubMed

Publication types

MeSH terms

LinkOut - more resources

  NODES
twitter 2